Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.52 |
| ▸ | HTR3B | O95264 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715672 | 1.00 | HTR3E (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1354442 | 0.93 | HTR3E (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6542062 | 0.85 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6542073 | 0.85 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6541318 | 0.85 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6422598 | 0.81 | CYP2A6 (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10349716 | 0.81 | MEN1 (0.73) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2291265 | 0.81 | MEN1 (0.73) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10017620 | 0.77 | MEN1 (0.75) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3283287 | 0.77 | MEN1 (0.75) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10069075-B2 | Charge-transporting varnish | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-09-04 | — | — | US | claimed |
| US-20160005975-A1 | CHARGE-TRANSPORTING VARNISH | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-01-07 | — | — | US | claimed |
| EP-2963699-A1 | CHARGE-TRANSPORTING VARNISH | Nissan Chemical Industries, Ltd. (JP) | 2016-01-06 | — | — | EP | claimed |
| EP-1379534-B1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS (DE) | 2004-12-15 | — | — | EP | claimed |
| EP-1379534-A1 | RHODIUM AND IRIDIUM COMPLEXES | Covion Organic Semiconductors GmbH (DE) | 2004-01-14 | — | — | EP | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2002081488-A1 | RHODIUM AND IRIDIUM COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2002-10-17 | — | — | WO | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| CN-110246870-B | Display device | 索尼公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-110085633-B | Display device | 索尼公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-105374850-B | Display device | 索尼公司 | 2020-03-17 | — | — | CN | disclosed |
| US-10069075-B2 | Charge-transporting varnish | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-10069075-B2 | Charge-transporting varnish | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| CN-103035665-B | Display of organic electroluminescence | 株式会社日本有机雷特显示器 | 2016-08-10 | — | — | CN | disclosed |
| US-6461538-B2 | Production process for indolizine compounds and their use in organic light-emitting devices | FUJI PHOTO FILM CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-20010015614-A1 | Novel indolizine compound, production process for novel indolizine compound, organic light-emitting device material having indolizine skeleton, and organic light-emitting device using these | UDC IRELAND LIMITED (IE) | 2001-08-23 | — | — | US | disclosed |
| US-6277907-B1 | STABILIZING THERMOPLASTIC RESINS AGAINST OXIDATIVE DEGRADATION | UNIROYAL CHEMICAL COMPANY, INC. | 2001-08-21 | — | — | US | disclosed |
| US-4229325-A | VULCANIZABLE COPOLYMERS OR TERPOLYMERS, A SULFUR DONOR, A DELAYED ACTION ACCELERATOR; GEL-FREE | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4151343-A | High unsaturation butyl rubbers | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010015614-A1 | Novel indolizine compound, production process for novel indolizine compound, organic light-emitting device material having indolizine skeleton, and organic light-emitting device using these | INMT, IDO1, INTS9 | HTR3E 104/4885HTR3B 202/4885HTR3A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.